Analysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment

被引：2
|
作者：
Provencio, M.
Cobo, M.
Vazquez-Estevez, S.
Firvida, J.
Macia, S.
Barneto, I.
Oramas, J.
Sanchez-Hernandez, A.
Ferrer, N.
Paredes, A.
机构：
[1] Hosp Puerta de Hierro, Madrid, Spain
[2] Hosp Univ Carlos Haya, Malaga, Spain
[3] Complexo Xeral Calde, Lugo, Spain
[4] Complexo Hosp Ourense, Orense, Spain
[5] Hosp Gen Elda, Elda, Spain
[6] Hosp Univ Reina Sofia, Dept Clin Oncol, Cordoba, Spain
[7] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
[8] Hosp Prov Castellon, Castellon de La Plana, Spain
[9] Hosp Son Llatzer, Palma De Mallorca, Spain
[10] Hosp Donostia, San Sebastian, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18109
引用
收藏
页数：1
相关论文
共 50 条
  • [31] BUDGET IMPACT ANALYSIS OF IMMUNOTHERAPY AS SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AT MEXICO'S NATIONAL INSTITUTE OF CANCER
    Barron-Barron, F.
    Meneses-Garcia, A. A.
    Rivera, L. M.
    de la Garza-Salazar, J.
    Cardona, A. F.
    Arrieta, O. G.
    Chavez Millan, F.
    Palafox Torres, D.
    Paladio Hernandez, J. A.
    VALUE IN HEALTH, 2019, 22 : S459 - S460
  • [32] EFFICACY AND SAFETY OF PEMETREXED AS SECOND-LINE TREATMENT IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE ANALYSIS
    Passaro, A.
    Pochesci, A.
    Palleschi, M.
    Pellegrino, A.
    Fabbri, M. A.
    Urbano, F.
    Gentile, V.
    Manai, C.
    Pavese, I.
    Cortesi, E.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S70 - S70
  • [33] Efficacy and safety analysis of anlotinib combined with immunotherapy as second-line therapy for advanced non-small cell lung cancer (NSCLC)
    Shi, Q.
    Xie, Q.
    Lin, H.
    He, Y.
    Zheng, X.
    Zhou, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1568 - S1568
  • [34] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    VALUE IN HEALTH, 2019, 22 : S165 - S166
  • [35] Single agents in the second-line treatment of non-small cell lung cancer
    Belani, CP
    SEMINARS IN ONCOLOGY, 1998, 25 (03) : 10 - 14
  • [36] An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer
    Scagliotti, G
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (16) : 2855 - 2866
  • [37] Geographic variation in the second-line treatment of non-small cell lung cancer
    Edelman, MJ
    Sekine, I
    Tamura, T
    Saijo, N
    SEMINARS IN ONCOLOGY, 2006, 33 (01) : S39 - S44
  • [38] The safety of second-line treatment options for non-small cell lung cancer
    Rossi, Antonio
    Maione, Paolo
    Santabarbara, Giuseppe
    Sacco, Paola Claudia
    Casaluce, Francesca
    Sgambato, Assunta
    Barzelloni, Maria Luisa
    Palazzolo, Giovanni
    Gridelli, Cesare
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 471 - 479
  • [39] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
    Pesek, M
    Holá, V
    LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
  • [40] Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment
    Caceres-Lavernia, Haslen H.
    Neninger-Vinageras, Elia
    Varona-Rodriguez, Leslie M.
    Olivares-Romero, Yoli A.
    Sanchez-Rojas, Irlis
    Mazorra-Herrera, Zaima
    Basanta-Bergolla, Denenke
    Duvergel-Calderin, Dayanis
    Torres-Cuevas, Boris L.
    del Castillo-Carrillo, Concepcion
    MEDICC REVIEW, 2021, 23 (3-4) : 21 - 28
12345